TPCW
BIO icon

TD Private Client Wealth’s Bio-Rad Laboratories Class A BIO Stock Holding History

TD Private Client Wealth’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$294 Buy
+1
New +$284 ﹤0.01% 1614
2025
Q2 		– Sell
-23
Closed -$5.6K – 1421
2025
Q1 		$5.6K Buy
23
+3
+15% +$902 ﹤0.01% 1070
2024
Q4 		$6.57K Sell
20
-51
-72% -$17.3K ﹤0.01% 1090
2024
Q3 		$23.8K Sell
71
-1
-1% -$318 ﹤0.01% 946
2024
Q2 		$19.7K Sell
72
-62
-46% -$18K ﹤0.01% 952
2024
Q1 		$46.3K Sell
134
-641
-83% -$211K ﹤0.01% 826
2023
Q4 		$250K Sell
775
-2,163
-74% -$678K 0.01% 524
2023
Q3 		$1.05M Sell
2,938
-48
-2% -$18.5K 0.05% 312
2023
Q2 		$1.13M Buy
2,986
+29
+1% +$11.8K 0.05% 310
2023
Q1 		$1.42M Buy
2,957
+282
+11% +$132K 0.06% 274
2022
Q4 		$1.12M Buy
2,675
+203
+8% +$81.9K 0.05% 300
2022
Q3 		$1.03M Buy
2,472
+202
+9% +$101K 0.05% 302
2022
Q2 		$1.12M Buy
2,270
+81
+4% +$42.2K 0.05% 298
2022
Q1 		$1.23M Buy
2,189
+322
+17% +$194K 0.05% 310
2021
Q4 		$1.41M Sell
1,867
-373
-17% -$279K 0.06% 289
2021
Q3 		$1.67M Buy
2,240
+85
+4% +$63.7K 0.07% 264
2021
Q2 		$1.39M Buy
2,155
+23
+1% +$14K 0.06% 289
2021
Q1 		$1.22M Buy
2,132
+447
+27% +$265K 0.06% 295
2020
Q4 		$982K Sell
1,685
-239
-12% -$136K 0.05% 303
2020
Q3 		$992K Sell
1,924
-26
-1% -$13.2K 0.06% 294
2020
Q2 		$880K Buy
1,950
+695
+55% +$307K 0.05% 298
2020
Q1 		$440K Buy
1,255
+272
+28% +$100K 0.03% 337
2019
Q4 		$364K Buy
+983
New +$347K 0.02% 390

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

TD Private Client Wealth's BIO Position: Q2 2026 in Review

TD Private Client Wealth opened a new position in Bio-Rad Laboratories Class A (BIO) in Q2 2026: 1 share worth $294. The stake represents ﹤0.01% of the portfolio and ranks #1614 among its holdings. This is a return to the name: TD Private Client Wealth previously reported a position in BIO as recently as Q1 2025.

TD Private Client Wealth first reported a position in BIO in Q4 2019 and has held it in 23 quarters since. The position peaked at $1.67M in Q3 2021. 399 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • TD Private Client Wealth held 1 share of Bio-Rad Laboratories Class A worth $294 as of Q2 2026.
  • Bio-Rad Laboratories Class A was a new TD Private Client Wealth position in Q2 2026.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #1614 holding.
  • TD Private Client Wealth first reported a position in Bio-Rad Laboratories Class A in Q4 2019 and has held it in 23 quarters since.
  • TD Private Client Wealth's Bio-Rad Laboratories Class A position peaked at $1.67M in Q3 2021.
  • 399 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.